Subscribe To

Price Alert Latest News Economic Calendar News

ONCY / Oncolytics Biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancreatic cancer trial

The stock of Oncolytics Biotech Inc. ONCY, +23.25% soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selected for inclusion in a an adaptive phase 3 pancreatic cancer clinical trial. An adaptive clinical trial is one which allows modifications to the trial or statistical procedures in the trial after it has been initiated. Read More

Demo Live Account See Partner Details

Content Topics

Oncolytics

Biotech

Stock

Soars

After

Pelareorep

Selected

Biotech s

Inclusion

Late stage

Pancreatic

Cancer

ONCY

Posted: Jun 22 2023, 13:12

Author Name: Market Watch

ONCY News

By Seeking Alpha
November 3, 2023

Oncolytics Biotech Inc. (ONCY) Q3 2023 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, IR Mat

By Zacks Investment Research
August 17, 2023

After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)

The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this

By Seeking Alpha
August 14, 2023

Oncolytics Biotech Inc. (ONCY) Q2 2023 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Jon Patton - Director-Investor

By Seeking Alpha
July 3, 2023

Oncolytics: Proof Of Concept In 2 Large Market Indications

Positive results achieved, in using pelareorep + paclitaxel for the treatment of HR+/HER2- metastatic breast cancer patients, in the phase 2 BRACELET-

By Market Watch
June 22, 2023

Oncolytics Biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancreatic cancer trial

The stock of Oncolytics Biotech Inc. ONCY, +23.25% soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selecte

By PRNewsWire
April 12, 2023

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

SAN DIEGO and CALGARY, AB , April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Off

By Seeking Alpha
March 3, 2023

Oncolytics Biotech Inc. (ONCY) Q4 2022 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q4 2022 Earnings Conference Call March 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, Investor

By Zacks Investment Research
January 18, 2023

New Strong Buy Stocks for January 18th

DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.